Aarti Pharma Labs Current Share Price | Aarti Pharma Labs Stock Screener
AARTIPHARM
Pharmaceuticals
Aarti Pharma Labs Current Stock Price Today
Live Share Price NSE
₹826.95
▲
1.20 (0.15%)
Live Share Price BSE
₹828.85
▲
3.85 (0.47%)
As of September 11, 2026, the live Aarti Pharma Labs share price (NSE: AARTIPHARM) is ₹826.95 on NSE and ₹828.85 on BSE, up 0.15% from the previous close, with shares trading between ₹814.00 and ₹833.00 in today's trading session, and a 52-week range of ₹591.95–₹938.95.
Browse AARTIPHARM financial statements to support your investment research.
Use the Aarti Pharma Labs stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Aarti Pharma Labs Market Cap
₹7,860.03 Cr.
AARTIPHARM P/E Ratio (TTM)
36.65
Aarti Pharma Labs P/B Ratio
3.68
EPS (TTM)
₹19.27
Dividend Yield
0.41%
Debt to Equity
0.19
AARTIPHARM 52 Week High
₹938.95
Aarti Pharma Labs 52 Week Low
₹591.95
Operating Margin
25.00%
Profit Margin
13.97%
AARTIPHARM Revenue (TTM)
₹544.00
EBITDA
₹144.00
Net Income
₹76.00
Total Assets
₹3,482.00
Total Equity
₹2,125.00
Aarti Pharma Labs Current Share Price Chart
Track the current Aarti Pharma Labs share price and stock price with an interactive chart. Analyse AARTIPHARM price trends, trading volume, historical performance, and volatility across different timeframes — the complete Aarti Pharma Labs stock quote in one place.
Aarti Pharma Labs Company Profile - Fundamental Screener
Screen Aarti Pharma Labs company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for AARTIPHARM shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE0LRU01027
Aarti Pharma Labs Balance Sheet Screener
Screen AARTIPHARM balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Assets | ||||||
| Total Assets | 3,482 | 2,906 | 2,582 | 2,244 | 2,040 | 0 |
| Current Assets | 1,397 | 1,322 | 1,346 | 1,163 | 1,028 | 0 |
| Fixed Assets | 1,831 | 1,137 | 1,033 | 926 | 782 | 0 |
| Liabilities | ||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 420 | 259 | 131 | 85 | 73 | 0 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||
| Total Equity | 2,125 | 1,990 | 1,757 | 1,559 | 1,387 | 0 |
| Share Capital | 45 | 45 | 45 | 45 | 0 | 0 |
| Reserves & Surplus | 2,079 | 1,945 | 1,712 | 1,513 | 1,341 | 0 |
Aarti Pharma Labs Income Statement Screener - Profit & Revenue Analysis
Screen Aarti Pharma Labs income statement and profit fundamentals.
Analyze AARTIPHARM quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Aarti Pharma Labs share price evaluation.
| Item | 2026-Jun | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec | 2023-Sept | 2023-Jun | 2023-Mar | 2022-Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 544 | 596 | 437 | 418 | 388 | 562 | 543 | 463 | 558 | 508 | 450 | 441 | 459 | 486 | 472 |
| Expenses | 400 | 470 | 333 | 344 | 293 | 418 | 409 | 364 | 459 | 388 | 353 | 352 | 374 | 405 | 385 |
| EBITDA | 144 | 127 | 104 | 74 | 95 | 144 | 134 | 98 | 99 | 120 | 97 | 89 | 85 | 81 | 87 |
| Operating Profit % | 25.00% | 19.00% | 23.00% | 18.00% | 24.00% | 26.00% | 24.00% | 20.00% | 17.00% | 23.00% | 21.00% | 20.00% | 19.00% | 16.00% | 18.00% |
| Depreciation | 30 | 28 | 29 | 25 | 23 | 23 | 23 | 21 | 20 | 19 | 19 | 18 | 17 | 16 | 16 |
| Interest | 13 | 17 | 13 | 11 | 7 | 7 | 10 | 6 | 5 | 5 | 5 | 4 | 4 | 6 | 5 |
| Profit Before Tax | 101 | 82 | 63 | 39 | 65 | 115 | 101 | 72 | 74 | 96 | 74 | 67 | 64 | 59 | 65 |
| Tax | 25 | 21 | 15 | 11 | 16 | 26 | 27 | 17 | 18 | 31 | 21 | 15 | 17 | 16 | 17 |
| Net Profit | 76 | 61 | 48 | 28 | 50 | 88 | 74 | 55 | 56 | 65 | 53 | 52 | 47 | 43 | 48 |
| EPS | 8.40 | 6.74 | 5.29 | 3.08 | 5.46 | 9.75 | 8.16 | 6.03 | 6.12 | 7.20 | 5.82 | 5.72 | 5.20 | 4.73 | 5.26 |
Aarti Pharma Labs Cash Flow Screener - Liquidity Fundamentals
Screen AARTIPHARM cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March |
|---|---|---|---|---|---|
| Operating Activities | 332 | 216 | 250 | -44 | 0 |
| Investing Activities | -414 | -215 | -158 | -139 | 0 |
| Financing Activities | 65 | 10 | -164 | 260 | 0 |
| Net Cash Flow | -17 | 12 | -71 | 78 | 0 |
Aarti Pharma Labs Shareholding Pattern Screener
See Aarti Pharma Labs shareholding pattern with promoter, FII, and DII holdings.
Check Aarti Pharma Labs promoter holding and ownership changes for AARTIPHARM on TickJournal.
| Item | 2026-Jun | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Mar | 2024-Jun |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 42.86% | 43.08% | 43.10% | 42.88% | 43.72% | 44.29% | 46.46% | 46.46% |
| FII Holding | 8.17% | 8.39% | 7.68% | 8.02% | 7.35% | 7.36% | 8.32% | 7.06% |
| DII Holding | 7.22% | 7.41% | 7.66% | 6.96% | 7.80% | 7.53% | 9.97% | 11.47% |
| Govt Holding | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% |
| Public Holding | 34.39% | 34.29% | 34.85% | 35.39% | 34.43% | 34.10% | 29.71% | 29.57% |
| Other Holding | 7.35% | 6.82% | 6.70% | 6.74% | 6.69% | 6.71% | 5.52% | 5.43% |
| Shareholder Count | 176,506 | 179,373 | 184,489 | 190,655 | 187,039 | 196,314 | 204,122 | 189,012 |
Aarti Pharma Labs Share Dividend Screener - Share Yield Analysis
Check Aarti Pharma Labs dividend history with payout and yield data.
View Aarti Pharma Labs dividend details including ex-dates and amounts for AARTIPHARM stock.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹5.00 | 0.84% |
| 2024-March | ₹3.00 | 0.40% |
| 2023-March | ₹2.00 | 0.46% |
| 2022-March | ₹0.00 | 0.00% |
| 2021-March | ₹0.00 | 0.00% |
| 2020-March | ₹0.00 | 0.00% |
| 2019-March | ₹0.00 | 0.00% |
| 2018-March | ₹0.00 | 0.00% |
| 2017-March | ₹0.00 | 0.00% |
Aarti Pharma Labs Stock Index Membership
See which indices include Aarti Pharma Labs stock.
Check AARTIPHARM index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
BSE 1000
BSE INDEX BSE HC
BSE INDEX SMLCAP
NIFTY MICROCAP250
NIFTY TOTAL MKT
Aarti Pharma Labs Market Events Screener - Corporate Actions
Get Aarti Pharma Labs corporate actions including splits, bonuses, and buybacks.
Check Aarti Pharma Labs stock events that may affect AARTIPHARM share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-09-22 | 2026-09-22 | Annual General Meeting | NA | 1.35% |
| 2026-09-15 | 2026-09-15 | Dividend | ₹ 2.00 /share | 20.97% |
| 2026-08-07 | 2026-08-07 | Quarterly Result Announcement | NA | 1.15% |
| 2026-05-25 | 2026-05-25 | Quarterly Result Announcement | NA | -6.93% |
| 2026-02-16 | 2026-02-16 | Dividend | ₹ 1.50 /share | -8.80% |
| 2026-02-09 | 2026-02-09 | Quarterly Result Announcement | NA | 2.01% |
| 2025-11-09 | 2025-11-09 | Quarterly Result Announcement | NA | 3.94% |
| 2025-09-22 | 2025-09-22 | Annual General Meeting | NA | 9.96% |
| 2025-09-15 | 2025-09-15 | Dividend | ₹ 2.50 /share | 20.75% |
| 2025-08-12 | 2025-08-12 | Quarterly Result Announcement | NA | -5.93% |
| 2025-05-10 | 2025-05-10 | Quarterly Result Announcement | NA | 1.74% |
| 2025-02-14 | 2025-02-14 | Dividend | ₹ 2.50 /share | 17.73% |
| 2025-02-05 | 2025-02-05 | Quarterly Result Announcement | NA | 4.01% |
| 2024-10-28 | 2024-10-28 | Quarterly Result Announcement | NA | -0.82% |
| 2024-08-07 | 2024-08-07 | Annual General Meeting | NA | -2.08% |
Aarti Pharma Labs Competitors Screener - Peer Comparison
Screen AARTIPHARM competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 452,491 | 37.62 | 61,674 | 12.69% | 11,565 | 42.08 |
| Divis Laboratories | 254,186 | 84.45 | 11,067 | 13.95% | 2,568 | 73.44 |
| Torrent Pharmaceuticals | 188,662 | 86.68 | 13,886 | 20.34% | 2,138 | 51.61 |
| Zydus Life Science | 115,264 | 25.09 | 27,658 | 17.64% | 5,026 | 50.98 |
| Cipla | 111,806 | 33.60 | 29,045 | 2.24% | 3,870 | 37.48 |
| Laurus Labs | 105,105 | 92.58 | 6,868 | 22.01% | 890 | 66.90 |
| Aurobindo Pharma | 97,354 | 25.71 | 34,145 | 5.56% | 3,503 | 60.75 |
| Lupin | 96,234 | 17.34 | 29,039 | 26.75% | 5,356 | 25.42 |
| Dr Reddys Laboratories | 96,070 | 30.02 | 35,059 | 3.90% | 4,158 | 40.13 |
| Mankind Pharma | 95,361 | 46.39 | 14,636 | 14.85% | 1,938 | 36.72 |
Aarti Pharma Labs Company Announcements - News Screener
Screen AARTIPHARM latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-09-06 | Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 | - |
| 2026-09-04 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-09-03 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-09-02 | Business Responsibility and Sustainability Reporting (BRSR) | - |
| 2026-09-02 | Notice Of 7Th Annual General Meeting Of The Company | - |
| 2026-09-02 | Reg. 34 (1) Annual Report. | - |
| 2026-08-18 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-17 | Record Date For Dividend For FY 2025-26 | - |
| 2026-08-17 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | - |
| 2026-08-10 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | - |
| 2026-08-10 | Announcement under Regulation 30 (LODR)-Investor Presentation | - |
| 2026-08-09 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-07 | Announcement under Regulation 30 (LODR)-Change in Directorate | - |
| 2026-08-07 | Approved Capacity Addition For Development Of Intermediate Block | - |
| 2026-08-07 | Announcement under Regulation 30 (LODR)-Change in Directorate | - |
| 2026-08-07 | Approval Of Unaudited Financial Results (Standalone And Consolidated)For The Quarter Ended June 30 2026 | - |
| 2026-08-07 | Board Meeting Outcome for Outcome Of Board Meeting Held On August 07 2026. | - |
| 2026-08-03 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-07-28 | Board Meeting Intimation for Unaudited Financial Results For The Quarter Ended June 30 2026. | - |
| 2026-07-07 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |